Dynamic QuantiFERON response in psoriasis patients taking long-term biologic therapy

Dermatology and Therapy

Volumn 3, Issue 1, 2013, Pages 73-81

  Drago, Lorenzo ^a,b   Nicola, Lucia ^a   Signori, Valentina ^a   Palazzi, Elisa ^a   Garutti, Cecilia ^a   Spadino, Samantha ^a   Altomare, Gianfranco ^a  

^a IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Biologic drugs; Chemoprophylaxis; Dermatology; False positive; Isoniazid; Psoriasis; QuantiFERON; Tuberculosis

Indexed keywords

ADALIMUMAB; EFALIZUMAB; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; ISONIAZID;

ADULT; AGED; ARTICLE; CHEMOPROPHYLAXIS; DIAGNOSTIC KIT; ENZYME LINKED IMMUNOSPOT ASSAY; FALSE POSITIVE RESULT; FEMALE; HUMAN; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84899817954     PISSN: None     EISSN: 21909172     Source Type: Journal    
DOI: 10.1007/s13555-013-0020-3     Document Type: Article

References (34)

1. Carmona L, Gómez-Reino JJ, Rodri{dotless}́guez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52:1766-72.
2. González-Salazar F, Vargas-Villarreal J, Rivera G, et al. Snapshot of Quantiferon TB gold testing in Northern Mexico. Tuberculosis (Edinb). 2011;91: S34-7.
3. Leung EC, Leung CC, Leung WW, et al. Role of whole-blood interferon-gamma release assay in the diagnosis of smear negative tuberculosis. Int J Tuberc Lung Dis. 2010;14:1564-70.
4. Chiappini E, Fossi F, Bonsignori F, Sollai S, Galli L, de Martino M. Utility of interferon-gamma release assay results to monitor anti-tubercular treatment in adults and children. Clin Ther. 2012;34:1041-8.
5. Bautista J, Banaei N. Sensitivity of QuantiFERON-TB GOLD In-Tube for diagnosis of recent versus remote M. tuberculosis infection. Diagn Microbiol Infect Dis. 2012;73:257-9.
6. Sotgiu G. Diagnosis and treatment of latent tubercular infections. G Ital Med Lav Ergon. 2010; 32:264-8.
7. Mazurek GH, LoBue PA, Daley CL, et al. Comparison of a whole blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA. 2001;286:1740-7.
8. Panés J, Gomollón F, Taxonera C, Hinojosa J, Clofent J, Nos P. Crohn's disease: a review of current treatment with focus on biologics. Drugs. 2007;67:2511-37.
9. Mi{dotless}́nguez S, Latorre I, MateoL, et al. Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumor necrosis factor treatment. Clin Rheumatol. 2012;31:785-94.
10. Lalvani A, Nagvenkar P, Udwadia Z, et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis. 2001;183:469-77.
11. Connell TG, Curtis N, Ranganathan SC, Buttery JP. Performance of a whole blood interferon gammaassay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax. 2006;61:616-20.
12. Domi{dotless}́nguez J, Latorre I, Altet N, et al. Interferongamma-release assays to diagnose TB infection in immunocompromised individual. Expert Rev Respir Med. 2009;3:309-27.
13. Ravn P, Munk ME, Andersen AB, et al. Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol. 2005;12:491-6.
14. Ruhwald M, Dominguez J, Latorre I, et al. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis (Edinb). 2011;91: 260-7.
15. Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev. 2008;8:147-52.
16. Domi{dotless}́nguez J, Latorre I. Role of the T-cell interferon-gamma release assays in preventing reactivation of latent tuberculosis infection in immunosuppressed patients in treatment with anti-TNF agents. J Crohns Colitis. 2008;2:250-4.
17. Mancuso JD, Mazurek GH, Tribble D, et al. Discordance among commercially available diagnostics for latent tuberculosis infection. Am J Respir Crit Care Med. 2012;185:427-34.
18. Centers for Disease Control and Prevention. Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC, and the Infectious Disease Society of America. MMWR. 2005;54:1-81.
19. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferongamma based assay using new antigens. Am J Resp Crit Care Med. 2004;170:59-64.
20. QuantiFERON-TB Gold In-Tube assay (package insert). Valencia: Cellestis Inc.; 2009.
21. Sterry W, Barker J, Boheneke WH, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004;151:3-17.
22. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177-84.
23. Diel R, Goletti D, Ferrara G, et al. Interferon-gamma release assays for thediagnosis of latentMycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J. 2011;37:88-99.
24. Pathirana D, Nast A, Ormerod AD, et al. On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges. J Eur Acad Dermatol Venereol. 2010;24:1458-67.
25. Kobashi Y, Mouri K, Yagi S, et al. Clinical utility of QuantiFERON TB-2G test for elderly patients with active tuberculosis. Chest. 2008;133:1196-202.
26. Laffitte E, Janssens JP, Roux-Lombard P, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol. 2009;161: 797-800.
27. Chiu H, Hsueh P, Tsai T. Clinical experience of QuantiFERON(®)-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol. 2011;164:553-9.
28. Helwig U, Müller M, Hedderich J, Schreiber S. Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients. J Crohns Colitis. 2012;6:419-24.
29. Kazue H, Nobuyuki H, Toru M. Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. Respirology. 2008;13:468-72.
30. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. Annu Rev Immunol. 2000;18:309-45.
31. Chinen J, ShearerWT. Secondary immunodeficiency, including HIV infection. J Allergy Clin Immunol. 2010;125:S195-203.
32. Dewan PK, Grinsdale J, Kawamura LM. Low sensitivity of a whole blood interferon-gamma release assay for detection of active tuberculosis. Clin Infect Dis. 2007;44:69-73.
33. Hamdi H, Mariette X, Godot V, et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther. 2006;8:R114.
34. Sivamani RK, Goodarzi H, Garcia MS, et al. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clinic Rev Allerg Immunol. 2012 [Epub ahead of print].